Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- HCPs, Payers Spat over Extension of Add-On Fee Premiums Related to Drug Supply Issues
November 27, 2023
- As Leqembi Listing Approaches, Chuikyo OKs Coverage for PET Device and Diagnostics
November 27, 2023
- Ultragenyx’s Evinacumab, Alexion’s Danicopan Up for Japan Panel Review on Dec. 8
November 27, 2023
- Pool Fever Reaches Alert Level in Japan for 1st Time in Decade: NIID
November 27, 2023
- Japan Deeping Debate on LLP Copay Review; Focus Is on Exclusion Criteria, Payment Levels, G1/G2 Rule Change
November 27, 2023
- Japan Approves Label Expansions for Opdivo, Adcetris, and More
November 27, 2023
- Japan Grants Orphan Tags to MSD’s MK-3475A, 3 More Drugs
November 27, 2023
- COVID Vaccines to Join NIP for Ages 65-Plus from April, with Copay Required
November 24, 2023
- No Objections to Better Premiums, Easing of Re-Pricing as Incentives for Pediatric Drug Development: Chuikyo
November 24, 2023
- Chuikyo Reps Split on Nixing PMP Company Criteria; Many Back Review of Reduction Caps under Re-Pricing
November 24, 2023
- MHLW Proposes Posting Reported Drug Supply Concerns on Its Website
November 22, 2023
- Label Revisions Ordered for 5 Anticoagulants Agents
November 22, 2023
- LDP Health Division Head Calls for “Innovation Box” Tax Break: Hearing
November 22, 2023
- Chuikyo Offers No Objection to MHLW Proposal on SaMD Reimbursement Criteria
November 21, 2023
- MHLW Notification Outlines 2-Stage Approval Scheme for SaMD
November 21, 2023
- Provide “One-Stop Services” to Facilitate Multiregional Clinical Trials: Expert
November 21, 2023
- 1st G-Lasta Biosimilar Gets Japan Listing, Stelara Follow-On Not on Roster
November 21, 2023
- LDP Study Group Submits Proposal for FY2024 Reform, Urges Boosted Drug Price Premiums at Launch
November 21, 2023
- MOF Panel Renews Call for Full Execution of Annual Price Cuts, Urges LLP Copay Review: Budget Proposal
November 21, 2023
- Pilot Sales of Emergency Contraceptives without Prescription to Start on Nov. 28
November 20, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…